greeksoup/ stocks
Stocks / United States / TEVA / Insiders

Teva Pharmaceutical Industries Ltd. insider trading

In the last twelve months insiders at Teva Pharmaceutical Industries Ltd. filed 40 open-market sales worth $49.2 million and 0 open-market purchases, on Form 4 with the SEC. The latest: Savage Brian, Interim Chief Legal Officer, sold 4,503 shares at $38.69 on 18 September 2026, filed 22 September 2026.

TradedInsiderRoleTypeSharesPriceValueFiling
18 September 2026Savage BrianInterim Chief Legal OfficerSale4,503$38.69$174,221Form 4
18 September 2026Savage BrianInterim Chief Legal OfficerSale2,525$39.15$98,841Form 4
18 September 2026Savage BrianInterim Chief Legal OfficerSale314$38.70$12,153Form 4
18 September 2026Mignone RobertoDirectorSale367,600$39.06$14.4 millionForm 4
21 August 2026Weiss AmirChief Accounting OfficerSale6,945$37.61$261,224Form 4
21 August 2026Weiss AmirChief Accounting OfficerSale2,500$37.63$94,077Form 4
21 August 2026Satchi-Fainaro RonitDirectorSale415$37.25$15,459Form 4
17 August 2026Lippman EvanEVP, Business DevelopmentSale18,600$36.57$680,291Form 4
5 August 2026Zaks Tal ZviDirectorSale17$34.87$593Form 4
3 August 2026Jover PlacidSee "Remarks"Sale12,827$34.88$447,351Form 4
3 August 2026Hughes Eric ASee "Remarks"Sale25,578$34.88$892,051Form 4
18 June 2026Shields MatthewEVP, Global OperationsSale9,989$32.19$321,547Form 4
11 June 2026Kalif Eliyahu SharonEVP, Chief Financial OfficerSale106,563$34.10$3.6 millionForm 4
5 June 2026Francis Richard DPresident and CEOSale6,153$34.35$211,356Form 4
3 June 2026Shields MatthewEVP, Global OperationsSale16,195$32.87$532,330Form 4
14 May 2026Lippman EvanEVP, Business DevelopmentSale5,746$35.58$204,467Form 4
14 May 2026Lippman EvanEVP, Business DevelopmentSale35,912$35.58$1.3 millionForm 4
14 May 2026Kalif Eliyahu SharonEVP, Chief Financial OfficerSale153,251$35.61$5.5 millionForm 4
6 May 2026Weiss AmirChief Accounting OfficerSale10,679$36.00$384,444Form 4
5 May 2026Daniell RichardEVP, Europe CommercialSale30,000$35.40$1.1 millionForm 4
1 May 2026Sabag MarkSee "Remarks"Sale144,180$34.99$5.0 millionForm 4
30 April 2026Fox ChristineEVP, U.S. CommercialSale21,258$35.31$750,620Form 4
17 March 2026Sabag MarkSee "Remarks"Sale62,102$30.14$1.9 millionForm 4
5 March 2026Francis Richard DPresident and CEOSale20,025$31.67$634,160Form 4
5 March 2026Fox ChristineEVP, U.S. CommercialSale7,924$31.67$250,940Form 4
5 March 2026Hughes Eric ASee "Remarks"Sale9,533$31.67$301,895Form 4
5 March 2026Daniell RichardEVP, Europe CommercialSale17,295$31.67$547,705Form 4
5 March 2026Jover PlacidSee "Remarks"Sale14,150$31.67$448,108Form 4
5 March 2026Savage BrianInterim Chief Legal OfficerSale1,127$31.67$35,690Form 4
5 March 2026Shields MatthewEVP, Global OperationsSale17,295$31.67$547,705Form 4
4 March 2026Francis Richard DPresident and CEOSale23,393$32.46$759,442Form 4
4 March 2026Daniell RichardEVP, Europe CommercialSale33,512$32.46$1.1 millionForm 4
4 March 2026Daniell RichardEVP, Europe CommercialSale20,461$32.46$664,256Form 4
4 March 2026Daniell RichardEVP, Europe CommercialSale37,372$32.95$1.2 millionForm 4
4 March 2026Hughes Eric ASee "Remarks"Sale11,277$32.46$366,102Form 4
4 March 2026Fox ChristineEVP, U.S. CommercialSale9,098$32.46$295,362Form 4
4 March 2026Savage BrianInterim Chief Legal OfficerSale1,489$32.46$48,340Form 4
4 March 2026Savage BrianInterim Chief Legal OfficerSale1,186$32.46$38,503Form 4
3 March 2026Daniell RichardEVP, Europe CommercialSale62,250$32.36$2.0 millionForm 4
3 March 2026Daniell RichardEVP, Europe CommercialSale66,735$32.36$2.2 millionForm 4

Open-market purchases (code P) and sales (code S) only. Option exercises, grants, tax withholding and gifts are not shown. A filing with several lines appears once per line.

Source

Form 4 filings on EDGAR for Teva Pharmaceutical Industries Ltd.: the company's filing index.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install